Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Cory Benfield discusses the evolution of ...

Cartesian Growth Corp. III Class A ( (CGCT)) just unveiled an announcement. On December 17, 2025, Cartesian Growth Corporation III and Factorial Inc. signed a definitive business combination agreement ...

Factorial’s high-power, lightweight, solid-state batteries have demonstrated real-world performance, including over 1,200 km (745 miles) of driving range in vehicle testing and are being advanced ...

University of California spinout Addition Therapeutics has uncloaked, revealing “breakthrough” PRINT technology it hopes will fuel a new wave of genetic medicine. Addition emerges from stealth with ...

Vector databases emerged as a must-have technology foundation at the beginning of the modern gen AI era. What has changed over the last year, however, is that vectors, the numerical representations of ...

A home construction project has people in Fairfax County talking — and leaders reexamining building rules. A three-story addition going up in the Greenbriar neighborhood towers over most of the ...

Physics and Python stuff. Most of the videos here are either adapted from class lectures or solving physics problems. I really like to use numerical calculations without all the fancy programming ...

Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Cory Benfield discusses the evolution of ...

Cartesian's mRNA-based cell therapy offers a novel, outpatient approach for autoimmune diseases, eliminating the need for preconditioning chemotherapy. Lead candidate Descartes-08 showed promising ...

As part of the redesign of the Vector Addition simulation, we are introducing a new vector labeling system specifically for the Lab screen. This screen differs from others in that users can create up ...

Cartesian Therapeutics, Inc. has announced the enrollment of the first participant in its Phase 3 AURORA trial for Descartes-08, its lead cell therapy candidate aimed at treating myasthenia gravis (MG ...